期刊文献+

伊伐布雷定联合美托洛尔对心力衰竭患者心率变异性和QT离散度的影响 被引量:3

The effect of ivabradine combined with metoprolol on heart rate variability and QT dispersion in patients with heart failure
下载PDF
导出
摘要 目的 探讨伊伐布雷定联合美托洛尔对心力衰竭患者心率变异性和QT离散度的影响.方法 选择我院收治的慢性心力衰竭患者90例为研究对象,随机分为对照组和观察组,每组45例.在对症治疗的基础上,对照组患者应用美托洛尔进行治疗,而观察组患者在对照组的用药基础上加用伊伐布雷定治疗,连续治疗12周后对两组患者的心率变异性相关参数和QT离散度进行检测和比较.结果 治疗前,两组患者的各项参数指标之间差异无统计学意义(P>0.05);治疗后,两组患者的QT离散度明显缩短,而心率变异性相关参数SDNN、rMSSD、SDANN、RNN50均明显升高,与同组治疗前之间差异有统计学意义(P<0.05),且两组患者之间差异也有统计学意义(P<0.05);两组患者不良反应发生率之间差异无统计学意义(P>0.05).结论 联合应用伊伐布雷定和美托洛尔治疗慢性心力衰竭患者,可以明显缩短QT离散度,升高心率变异性. Objective To explore the effect of ivabradine combined with metoprolol on heart rate variability(HRV) and QT dispersion(QTd) in patients with heart failure. Methods 90 patients with chronic heart failure admitted to our hospital were selected as research subjects and randomly divided into the control group and the observation group, with 45 patients in each group. On the basis of symptomatic treatment, the patients of the control group were treated with metoprolol, while the patients of the observation group were treated with ivabradine based on metoprolol administered to the control group. After twelve weeks of continuous treatment, the HRV related parameters and QTd of the two groups were detected and compared. Results Before treatment, there was no statistically significant difference between the patients of the two groups in all parameters and indicators(P > 0.05). After treatment, QTd of the two groups of patients was significantly shortened, while the HRV related parameters such as SDNN, rMSSD, SDANN and RNN50 all significantly increased, with statistically significant difference from those before treatment in each group(P < 0.05), and the difference between the two groups of patients was also statistically significant(P < 0.05). There was no statistically significant difference in the incidence of adverse reactions(ADRs) between the two groups(P > 0.05). Conclusion Combined application of ivabradine and metoprolol in the treatment of the patients with chronic heart failure can significantly shorten QTd and increase HRV.
作者 薛丹 XUE Dan(ECG Room,Jiangyin People’s Hospital,Jiangsu,Jiangyin 214400,China)
出处 《中国医药科学》 2020年第14期85-87,共3页 China Medicine And Pharmacy
关键词 心力衰竭 伊伐布雷定 美托洛尔 心率变异性 QT离散度 Heart failure Ivabradine Metoprolol Heart rate variability(HRV) QT dispersion(QTd)
  • 引文网络
  • 相关文献

参考文献11

二级参考文献138

  • 1王方正,张澍,黄德嘉,华伟,孙宝贵,沈法荣,吴书林,王建安,方全,吴立群,王景峰,王冬梅,郭涛,陈新,中华医学会心电生理和起搏分会心脏再同步治疗专家工作组.心脏再同步治疗慢性心力衰竭的建议[J].中华心律失常学杂志,2006,10(2):90-102. 被引量:91
  • 2Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol, 1997, 80(11A) : 15L-25L
  • 3Braunwald E,Bristow MR Congestive heart failure: fifty years of progress. Circulation, 2000, 102(20 Suppl 4) : Ⅳ14-23.
  • 4Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure) : developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation, 2005, 112 (12) :e154-235.
  • 5Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary ( update 2005 ):The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J, 2005, 26(11): 1115-1140.
  • 6Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006 : diagnosis and management. Can J Cardiol, 2006, 22 (1): 23-45.
  • 7Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail, 2006, 12 ( 1 ) : e1-2.
  • 8Enright PL, Sherrill DL Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med, 1998, 158(5 pt 1) :1384-1387.
  • 9Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J, 1999, 14(2) : 270-274.
  • 10Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation, 2002, 105 (20):2328-2331.

共引文献3823

同被引文献59

引证文献3

二级引证文献3

;
使用帮助 返回顶部